+91 8617752708

British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol.: 18, Issue.: 3


Determining the Impact of Borderline Personality Disorder in the Treatment Outcome of Depression


Eric D. Peselow1, Ruby Mangsatabam2, Kimberly Smith1, Bret Becker1, Enrique Lopez1, Mehdi Farokhnia1, Monica Hanna1, Samantha Cohen1, Shaina Ganjian1, Jonathan Dang1 and Waguih William IsHak1,3*

1Cedars-Sinai Medical Center, Los Angeles, California, USA.

2Trinitas Medical Center, Elizabeth, New Jersey, USA.

3David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Article Information
(1) Thomas I. Nathaniel, University of South Carolina, School of Medicine-Greenville, Greenville, SC 29605, USA.
(1) Abdollah Alizadeh, Yerevan State University, Yerevan, Armenia.
(2) Sara Marelli, Vita-Salute San Raffaele University, Milan, Italy.
Complete Peer review History: http://www.sciencedomain.org/review-history/16510


Aim: To evaluate whether Borderline Personality Disorder (BPD) has an impact on the treatment outcome in patients with Major Depressive Disorder (MDD).

Methods: We studied 130 patients who met the DSM-IV criteria for MDD according to the DSM-IV checklist. Patients were assessed for depression and BPD using the Montgomery Asberg Depression Rating Scale (MADRS) and the Structured Clinical Interview for DSM-IV Personality Disorders (SIDP-IV), respectively. Each patient was assessed for depression severity using the MADRS score at the beginning of the study and once again after 8-12 weeks of Selective Serotonin Reuptake Inhibitor (SSRI) treatment. Results derived from MADRS evaluations of patients with MDD comorbid with BPD (MDD+BPD) were analyzed and compared with results from patients with MDD no comorbid BPD (MDDnoBPD). The rates of remission and response to treatment in these two groups were thereby measured and compared.

Results: Patients with MDD+BPD had statistically significantly lower rates of remission after SSRI treatment compared to patients with MDDnoBPD (P= .009). Interestingly, when comparing patients that had single episode of MDD, the difference in remission rates was not statistically significant (P= .07) in both groups. In contrast, when comparing patients with recurrent episode of MDD, remission rates were statistically significantly lower in patients with MDD+BPD (P= .03).

Conclusion: MDD+BPD patients have lower rates of remission when treated with SSRIs in comparison with MDDnoBPD. Therefore, it is important to assess MDD patients for additional personality disorders in order to structure an optimal treatment plan with clear prognostic indicators.

Keywords :

Borderline personality disorder; major depressive disorder; pharmacotherapy; outcome; comorbidity.

Full Article - PDF    Page 1-8

DOI : 10.9734/BJMMR/2016/29374

Review History    Comments

Our Contacts

Guest House Road, Street no - 1/6,
Hooghly, West Bengal,

+91 8617752708


Third Floor, 207 Regent Street
London, W1B 3HH,

+44 20-3031-1429